DermACELL is a technologically advanced Acellular Dermal Matrix (ADM) that can be used in breast reconstruction surgeries, as well as in the treatment of diabetic foot ulcers and chronic non-healing wounds. These allograft bio-implants are processed utilizing MATRACELL® and PRESERVON®, two of LifeNet Health’s patented and proprietary technologies. MATRACELL renders these implants acellular, without compromising the biomechanical or biochemical properties while PRESERVON allows them to be stored at room temperature and ready to use out of the packaging.

Dr. Arun Menawat, President and CEO of NOVADAQ, commented, "There is a proven, clinical and call point synergy between the use of tissue matrices and the ability to assess the quality of tissue perfusion. Accordingly, we believe that NOVADAQ’s SPY® fluorescence imaging technology, which enables the visual assessment of blood flow and tissue perfusion, complements LifeNet Health’s DermACELL product and as such, together provide a comprehensive solution for clinicians managing these complex conditions."

"Globally, there is a growing critical need for soft tissue allograft bio-implants," said LifeNet Health’s CEO, Rony Thomas. "We’re proud to pair our state-of-the-art products with NOVADAQ’s gold-standard perfusion assessment and wound imaging technolo-gy. We believe it will lead to improved outcomes for reconstructive and chronic wound patients, as well as reduce costs to the healthcare system."

The Agreement has an initial 10-year term and, subject to certain conditions and NOVADAQ fulfilling certain sales performance metrics, will automatically renew for successive five-year periods.